Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 7Recruiting 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hematologic Neoplasms 5Myelodysplastic Syndromes 4Tuberous Sclerosis 2Recurrence 2Primary Myelofibrosis 2Myeloproliferative Disorders 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Epilepsy 2Bronchiolitis Obliterans Syndrome 2Thyroid Neoplasms 1Solid Tumor 1Sarcoma 1Prostate Cancer Recurrent 1Non-Malignant Neoplasm 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphangioleiomyomatosis 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Sirolimus × Clear all
NCT07366801 2026-01-26

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Recruiting
64 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06743503 2025-09-18

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

Nanjing IASO Biotechnology Co., Ltd.

Phase 1 Recruiting
70 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡